Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak

  • Br J Haematol. 2020 Nov;191(3):386-389. doi: 10.1111/bjh.17066.
Beatriz de la Cruz-Benito  1 ,  Paula Lázaro-Del Campo  1 ,  Andrés Ramírez-López  1 ,  Teresa de Soto-Álvarez  1 ,  Irene Sánchez-Vadillo  1 ,  Eduardo García-Pérez  1 ,  Abel Dos Santos-Ortas  1 ,  Karem Humala-Barbier  1 ,  Ana López-de la Guía  1 ,  Gema Casado-Abad  2 ,  Victor Jiménez-Yuste  1 ,  Miguel Canales-Albendea  1
Affiliations
  • 1. Haematology Department, La Paz University Hospital, Madrid, Spain.
  • 2. Pharmacy Department, La Paz University Hospital, Madrid, Spain.
PMID: 32762043 DOI: 10.1111/bjh.17066
Abstract

The COVID-19 pandemic has dramatically challenged care for Cancer patients, especially those with active treatment who represent a vulnerable population for SARS-CoV-2 Infection. Aggressive lymphoid neoplasms, such as diffuse large B cell lymphoma and high-grade B cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed to minimise the risk of SARS-CoV-2 Infection while continuing haematological treatment. In this report, we analyse the management of front-line therapy in 18 patients during the COVID-19 outbreak, as well as the results of the implemented measures in their outcome.

Keywords
B cell lymphoma; COVID-19; SARS-CoV-2; haematological malignancies; high-grade.